Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of tTF-NGR in Patients With Recurrent or Refractory Malignant Tumors and Lymphomas Beyond All Standard Treatments

NCT02902237 is registered in ClinicalTrials.gov with University Hospital Muenster as lead sponsor.

NCT NCT02902237
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02902237 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of tTF-NGR in Patients With Recurrent or Refractory Malignant Tumors and Lymphomas Beyond All Standard Treatments
Lead sponsor
University Hospital Muenster
Phase
Phase 1
Overall status
Completed
Start date
March 1, 2017
Completion date
November 5, 2019
Enrollment
24 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lymphomas, malignant solid tumors